This New Novartis AG Drug May Revolutionize Heart Failure Treatment

Novartis LCZ696 may give doctors the first significant high blood pressure drug approved in decades if regulators give it the okay next year.

Sep 2, 2014 at 5:12PM

Doctors have long struggled to effectively treat heart failure caused by high blood pressure. ACE inhibitors, like enalapril -- formerly sold by Merck (NYSE:MRK) as the branded drug Vasotec, came on the scene in the 1990s, and ARB inhibitors, like Novartis' (NYSE:NVS) Diovan, which won approval in 1997, remain first line therapies in the fight to prevent heart disease.

However, despite those medicines being widely prescribed, high blood pressure remains inadequately treated and that means a greater percentage of people suffer heart failure every year. Estimates suggest that as many as 50% of those who should be taking drugs that lower blood pressure don't take them and discouragingly, only a third of those who do take them have their blood pressure under adequate control.

Fortunately, a new drug making its way to regulators from Novartis may offer patients new hope. This past weekend, Novartis released full study results from phase 3 trials of LCZ696, a combination therapy that is made up of the company's Diovan and a new drug, AHU-377.

Novartis

Source: Novartis

A changing market
According to Express Scripts, high blood pressure is the third highest cost indication behind diabetes and high cholesterol, but spending on ACE inhibitors and ARBs is expected to fall through at least 2016 due to the launch of new generic versions of the blockbuster Diovan.

Express Scripts thinks that generic Diovan will be just as successful as generic ACE inhibitors like lisinopril, which was formerly marketed by Merck and AstraZeneca. Lisinopril is among the most widely prescribed drugs in America, accounting for 16.6% market share of all high blood pressure medication.

If Express Scripts forecast is correct, switching to generic Diovan will result in spending on high blood pressure drugs falling 12% this year and another 11% more in both 2015 and 2016.

G

Source: Novartis

A new option
Novartis hasn't been shy in its attempts to broaden its Diovan franchise by developing combination therapies. Its Diovan HCT pairs up Diovan with a water pill and that drug pulled in sales of more than $1.5 billion a year before losing patent protection in 2012.

Novartis' Exforge, a combination of Diovan and a calcium channel blocker -- another popular blood pressure lowering medication -- has also been a big seller. Exforge sales totaled $1.4 billion last year; however, Exforge loses patent protection next month.

Rapidly falling sales for Diovan HCT, Diovan, and (soon) Exforge, Novartis is pinning hope on LCZ696, which matches up Diovan with AHU-377, a neprilysin enzyme inhibitor that stops the enzyme from damaging blood pressure-lowering peptides.

In phase 2 trials, patients receiving LCZ696 instead of Diovan had better control over their hypertension and a strong showing in phase 3 trials prompted independent monitors to halt the late stage study early.

This past weekend, Novartis presented the data behind the monitor's decision and that data may be compelling enough to turn LCZ696 into a blockbuster.

In the phase 3 trial, LCZ696 faced-off against enalapril and over a 27 week period, patients receiving LCZ696 showed both a lower rate of death and a lower rate of hospitalization for heart failure. Overall, 21.8% of those taking LCZ696 either died or had been hospitalized due to their condition, versus 26.5% for those taking enalapril.

Fool-worthy final thoughts
That 20% improvement is significant enough that Novartis plans to file for U.S. approval of LCZ696 later this year and European approval early next year.

Since there has been little improvement in drug therapy since Diovan, LCZ696 may find that both doctors and patients willingly embrace it. If that proves true, LCZ696 will go a long way to sure-ing up Novartis' sales in the face of mounting generic competition.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers